Bladder and Urothelial Cancer Treatments

SEP 8, 2026 · JOURNAL ARTICLE

Sex, Timing, and Outcomes of Curative-Intent Immunotherapy

JAMA Network Open

Large, rigorous meta-analysis of 38 randomized phase 3 trials with 31,721 patients showing statistically significant OS and disease-free survival benefits from ICIs in curative solid tumors, with no sex difference detected, though female underrepresentation limits generalizability.

SEP 8, 2026 · JOURNAL ARTICLE

Tertiary lymphoid structures in urothelial carcinoma: bridging spatial architecture with therapeutic vulnerability in the post-BCG era

Frontiers in Immunology

A narrative review synthesizing current evidence and raising mechanistic questions about tertiary lymphoid structures in urothelial carcinoma, without new empirical data or prospective validation of proposed biomarker relationships.

SEP 7, 2026 · REVIEW

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology

A systematic review synthesizing evidence on biomarkers for BCG therapy prediction in bladder cancer; provides a landscape assessment rather than a new empirical result, identifying gaps and promising directions for clinical practice.

SEP 7, 2026 · JOURNAL ARTICLE

Adjuvant therapy and fear of cancer recurrence in bladder cancer survivors: a cross-sectional pilot study

BMC Urology

A single-centre, underpowered cross-sectional pilot study explicitly designed as hypothesis-generating, with a null primary finding that the authors acknowledge cannot rule out a clinically meaningful effect.

SEP 5, 2026 · JOURNAL ARTICLE

Real-world outcomes and immune-related adverse events with PD-1/ PD-L1 inhibitors in metastatic renal cell carcinoma: A prospective observational study

Asian Journal of Oncology

Single-center prospective observational study with modest sample size (n=31) and surrogate endpoint (ORR at 3 months); demonstrates feasibility in a LMIC setting but lacks a comparator and control group, and requires confirmation in larger studies.

SEP 1, 2026 · JOURNAL ARTICLE

MMP9 Knockout by CRISPR ‐Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti‐ PD ‐ L1 in an Orthotopic Mouse Model

Iubmb Life

Early-phase in vivo mechanistic study in mice using CRISPR-Cas9 gene editing; demonstrates MMP9 knockout reduces bladder cancer malignancy but fails to achieve synergy with established immunotherapies, lacking human validation and clinical endpoints.

AUG 18, 2026 · JOURNAL ARTICLE

Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing advanced urothelial cancer

Human Vaccines & Immunotherapeutics

A modeled cost-effectiveness analysis from a single healthcare system showing the intervention meets the threshold, but dependent on assumptions about treatment duration and subsequent costs that proved sensitive in scenario testing.

AUG 18, 2026 · JOURNAL ARTICLE

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

Iju Case Reports

A single case report of unexpected response to checkpoint inhibition in a rare cancer subtype raises a mechanistic question but provides no comparative evidence, control group, or generalizable data.